SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Renin-Angiotensin-Aldosterone System
This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Remuzzi, A.
Right arrow Articles by Remuzzi, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Remuzzi, A.
Right arrow Articles by Remuzzi, G.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Reviews

Review: Potential protective effects of telmisartan on renal function deterioration

Andrea Remuzzi

Mario Negri Institute for Pharmacological Research, Via Gavazzeni, 11 24125 Bergamo, Italy, aremuzzi{at}marionegri.it

Giuseppe Remuzzi

Mario Negri Institute for Pharmacological Research, Via Gavazzeni, 11 24125 Bergamo, Italy, Unit of Nephrology and Dialysis, Azienda Ospedaliera, Ospedali Riuniti di Bergamo, Largo Barozzi, 1 24128 Bergamo, Italy

Experimental and clinical evidence is now available that antagonism of angiotensin II (Ang II) with both angiotensin-converting enzyme inhibitors and Ang II receptor antagonists (AIIAs) is effective in slowing the rate of renal functional loss in patients affected by proteinuric kidney diseases.Among AIIAs, telmisartan has been shown to be characterised by a potent and long lasting antihypertensive effect that may be associated with another specific effect of this molecule, the partial agonism of the peroxisome-activated receptor-gamma.Although this action has also been observed with other AIIAs, telmisartan seems to exert a more effective and specific action as in such a way to influence beneficially adipocyte metabolism, diabetes onset and insulin resistance. Recently, we have demonstrated, at the experimental and clinical level, that sustained blockade of Ang II biological activity with this class of compounds can potentially reduce the progression of renal dysfunction and in some circumstances induce the regression of renal functional and structural changes. In this review we analyse available experimental and clinical data that suggest that blocking Ang II with telmisartan may effectively ameliorate renal dysfunction in patients affected by the now frequently observed condition termed metabolic syndrome.

Key Words: angiotensin II peroxisome-activated receptor-gamma • angiotensin receptor antagonists • angiotensin-converting enzyme inhibitors • metabolic syndrome • insulin resistance renal diseases • renoprotection

References

  • Brenner BM Nephron adaptation to renal injury or ablation. Am J Physiol 1985;249:F324-F337.[Web of Science][Medline] [Order article via Infotrieve]
  • Remuzzi A., Puntorieri S., Alfano M. et al. Pathophysiologic implications of proteinuria in a rat model of progressive glomerular injury. Laboratory Investigation 1992;67:572-9.[Web of Science][Medline] [Order article via Infotrieve]
  • Benigni A., Zoja C., Remuzzi G. The renal toxicity of sustained glomerular protein traffic. Laboratory Investigation 1995;73:461-8.[Web of Science][Medline] [Order article via Infotrieve]
  • Benigni A., Remuzzi G. Glomerular protein trafficking and progression of renal disease to terminal uremia. Semin Nephrol 1996;16:151-9.[Web of Science][Medline] [Order article via Infotrieve]
  • Remuzzi A., Gagliardini E., Donadoni C. et al. Effect of angiotensin II antagonism on the regression of kidney disease in the rat. Kidney Int 2002;62:885-94.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Remuzzi G., Remuzzi A. Is regression of chronic nephropathies a therapeutic target? J Am Soc Nephrol 2005;16:840-2.[Free Full Text]
  • Remuzzi A., Gagliardini E., Sangalli F. et al. ACE inhibition reduces glomerulosclerosis and regenerates glomerular tissue in a model of progressive renal disease. Kidney Int 2006; 69:1124-30.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Sharpe M., Jarvis B., Goa KL Telmisartan: a review of its use in hypertension. Drugs 2001;61:1501-29.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Kakuta H., Sudoh K., Sasamata M., Yamagishi S. Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers. Int J Clin Pharmacol Res 2005;25:41-6.[Web of Science][Medline] [Order article via Infotrieve]
  • Battershill AJ, Scott LJ Telmisartan: a review of its use in the management of hypertension. Drugs 2006;66:51-83.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Redon J., Luque-Otero M., Martell N., Chaves FJ Renin-angiotensin system gene polymorphisms: relationship with blood pressure and microalbuminuria in telmisartan-treated hypertensive patients. Pharmacogenomics J 2005; 5:14-20.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Karlberg BE, Lins LE, Hermansson K. Efficacy and safety of telmisartan, a selective AT1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension. TEES Study Group. J Hypertens 1999;17:293-302.[Web of Science][Medline] [Order article via Infotrieve]
  • Benson SC, Pershadsingh HA, Ho CI et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004;43:993-1002.[Abstract/Free Full Text]
  • Schupp M., Janke J., Clasen R. et al. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004;109:2054-7.[Abstract/Free Full Text]
  • Sharma AM Telmisartan: the ACE of ARBs? Hypertension 2006;47:822-3.[Free Full Text]
  • Amerena J., Pappas S., Ouellet JP et al. ABPM comparison of the anti-hypertensive profiles of telmisartan and enalapril in patients with mild-to-moderate essential hypertension. J Int Med Res 2002;30:543-52.[Web of Science][Medline] [Order article via Infotrieve]
  • Ragot S., Ezzaher A., Meunier A. et al. Comparison of trough effect of telmisartan vs perindopril using self blood pressure measurement: EVERESTE study. J Hum Hypertens 2002;16:865-73.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Williams B., Gosse P., Lowe L., Harper R. The prospective, randomized investigation of the safety and efficacy of telmisartan versus ramipril using ambulatory blood pressure monitoring (PRISMA I). J Hypertens 2006;24:193-200.[Web of Science][Medline] [Order article via Infotrieve]
  • Ingino C., Farsang C., Laucevicius A., Bergovec M. An open-label study investigating the efficacy and safety of 12-96 weeks of telmisartan treatment in patients with hypertension. J Int Med Res 2003;31:561-74.[Web of Science][Medline] [Order article via Infotrieve]
  • Janke J., Engeli S., Gorzelniak K. et al. Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin type 1 receptors. Diabetes 2002;51:1699-707.[Abstract/Free Full Text]
  • Sharma AM Is there a rationale for angiotensin blockade in the management of obesity hypertension? Hypertension 2004;44:12-19.[Abstract/Free Full Text]
  • Engeli S., Bohnke J., Gorzelniak K. et al. Weight loss and the renin-angiotensin-aldosterone system. Hypertension 2005; 45:356-62.[Abstract/Free Full Text]
  • Tang WH Do thiazolidinediones cause heart failure? A critical review. Cleve Clin J Med 2006;73:390-7.[Abstract/Free Full Text]
  • Irons BK, Greene RS, Mazzolini TA et al. Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus. Pharmacotherapy 2006;26:168-81.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Oberfield JL, Collins JL, Holmes CP et al. A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation. Proc Natl Acad Sci USA 1999;96:6102-06.[Abstract/Free Full Text]
  • Willson TM, Brown PJ, Sternbach DD, Henke BR The PPARs: from orphan receptors to drug discovery. J Med Chem 2000;43:527-50.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Sugimoto K., Qi NR, Kazdova L. et al. Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis. Hypertension 2006;47:1003-09.[Abstract/Free Full Text]
  • Ouchi N., Kihara S., Funahashi T. et al. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 2003;107:671-4.[Abstract/Free Full Text]
  • Arita Y., Kihara S., Ouchi N. et al. Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation 2002;105:2893-8.[Abstract/Free Full Text]
  • Matsuda M., Shimomura I., Sata M. et al. Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. J Biol Chem 2002;277:37487-91.[Abstract/Free Full Text]
  • Wassmann S., Hilgers S., Laufs U. et al. Angiotensin II type 1 receptor antagonism improves hypercholesterolemiaassociated endothelial dysfunction. Arterioscler Thromb Vasc Biol 2002;22:1208-12.[Abstract/Free Full Text]
  • Wassman S., Czech T., van Eickels M. et al. Inhibition of diet-induced atherosclerosis and endothelial dysfunction in apolipoprotein e/anglotensin II type 1a receptor double-knockout mice. Circulation 2004;110:3062-7.[Abstract/Free Full Text]
  • Imanishi T., Hano T., Nishio I. Angiotensin II accelerates endothelial progenitor cell senescence through induction of oxidative stress. J Hypertens 2005;23:97-104.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Fujimoto M., Masuzaki H., Tanaka T. et al. An angiotensin II AT1-receptor antagonist, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes. FEBS Lett 2004;576:492-7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Fogari R., Lazzari P., Zoppi A. Effect of telmisartan losartan and lisinopril on insulin sensitivity in hypertensive patients with and without insulin resistance. Eur Heart J 2004;25:78.
  • Koulouris S., Symeonides P., Triantafyllou K. et al. Comparison of the effects of ramipril versus telmisartan in reducing serum levels of high-sensitivity C-reactive protein and oxidized low-density lipoprotein cholesterol in patients with type 2 diabetes mellitus. Am J Cardiol 2005;95:1386-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Remuzzi A., Perico N., Sangalli F. et al. ACE inhibition and ANG II receptor blockade improve glomerular size-selectivity in IgA nephrology. Am J Physiol 1999;276:F457-66.[Web of Science][Medline] [Order article via Infotrieve]
  • Brenner BM, Cooper ME, de Zeeuw D. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.[Abstract/Free Full Text]
  • Strippoli GF, Craig M., Craig JC Antihypertensive agents for preventing diabetic kidney disease. Cochrane Database Syst Rev:CD004136, 2005.
  • Ruggenenti P., Schieppati A., Remuzzi G. Progression, remission, regression of chronic renal diseases. Lancet 2001;357:1601-08.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Barnett A. Preventing renal complications in type 2 diabetes: results of the diabetics exposed to telmisartan and enalapril trial. J Am Soc Nephrol 2006;17:S132-S135.[Abstract/Free Full Text]
  • Sugiyama H., Kobayashi M., Wang DH et al. Telmisartan inhibits both oxidative stress and renal fibrosis after unilateral ureteral obstruction in acatalasemic mice. Nephrol Dial Transplant 2005;20:2670-80.[Abstract/Free Full Text]

Journal of Renin-Angiotensin-Aldosterone System, Vol. 7, No. 4, 185-191 (2006)
DOI: 10.3317/jraas.2006.036
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Remuzzi, A.
Right arrow Articles by Remuzzi, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Remuzzi, A.
Right arrow Articles by Remuzzi, G.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Advertisement